Research Article

You have full text access to this OnlineOpen article

Selective inhibition of activin receptor–like kinase 5 signaling blocks profibrotic transforming growth factor β responses in skin fibroblasts

  1. Yasuji Mori1,
  2. Wataru Ishida1,
  3. Swati Bhattacharyya1,
  4. Yongzhong Li2,
  5. Leonidas C. Platanias2,
  6. John Varga1,*

Article first published online: 8 DEC 2004

DOI: 10.1002/art.20658

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 50, Issue 12, pages 4008–4021, December 2004

Additional Information

How to Cite

Mori, Y., Ishida, W., Bhattacharyya, S., Li, Y., Platanias, L. C. and Varga, J. (2004), Selective inhibition of activin receptor–like kinase 5 signaling blocks profibrotic transforming growth factor β responses in skin fibroblasts. Arthritis & Rheumatism, 50: 4008–4021. doi: 10.1002/art.20658

Author Information

  1. 1

    University of Illinois College of Medicine, Chicago

  2. 2

    Northwestern University School of Medicine, Chicago, Illinois

*Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, 240 East Huron Street, McGaw 2300, Chicago, IL 60611-2909

Publication History

  1. Issue published online: 8 DEC 2004
  2. Article first published online: 8 DEC 2004
  3. Manuscript Accepted: 23 AUG 2004
  4. Manuscript Received: 1 MAR 2004

Funded by

  • NIH. Grant Number: (AR-42309)
  • Scleroderma Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (957K)

REFERENCES

  • 1
    Trojanowska M. Molecular aspects of scleroderma. Frontiers Biosci 2002; 7: d608–18.
  • 2
    Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000; 342: 1350–8.
  • 3
    Massague J. How cells read TGF-β signals. Nat Rev Mol Cell Biol 2000; 1: 169–78.
  • 4
    Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 2002; 7: 1191–204.
    Direct Link:
  • 5
    Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000; 97: 2626–31.
  • 6
    Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003; 425: 577–84.
  • 7
    Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62: 65–74.
  • 8
    Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, et al. Identification of novel inhibitors of the transforming growth factor β1 type 1 receptor (ALK5). J Med Chem 2002; 45: 999–1001.
  • 9
    Mori Y, Chen SJ, Varga J. Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-β. Exp Cell Res 2000; 258: 374–83.
  • 10
    Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003; 48: 1964–78.
    Direct Link:
  • 11
    Jelaska A, Korn JH. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000; 43: 2230–9.
    Direct Link:
  • 12
    Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998; 1: 611–7.
  • 13
    Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 1997; 89: 1165–73.
  • 14
    Ghosh AK, Yuan W, Mori Y, Chen SJ, Varga J. Antagonistic regulation of type I collagen gene expression by interferon-γ and transforming growth factor-β: integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 2001; 276: 11041–8.
  • 15
    Li Y, Sassano A, Majchrzak B, Deb DK, Levy DE, Gaestel M. Role of p38α MAP kinase in type I interferon signaling. J Biol Chem 2004; 279: 970–9.
  • 16
    Hashimoto S, Gon Y, Takeshita I, Maruoka S, Horie T. IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase-dependent pathway. J Allergy Clin Immunol 2001; 107: 1001–8.
  • 17
    Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000; 292: 988–94.
  • 18
    Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349–63.
  • 19
    Evans RA, Tian YC, Steadman R, Phillips AO. TGF-β1-mediated fibroblast-myofibroblast terminal differentiation: the role of Smad proteins. Exp Cell Res 2003; 282: 90–100.
  • 20
    Vaughan MB, Howard EW, Tomasek JJ. Transforming growth factor-β1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res 2000; 257: 180–9.
  • 21
    Hocevar BA, Brown TL, Howe PH. TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 1999; 18: 1345–56.
  • 22
    Isono M, Chen S, Hong SW, Iglesias-de la Cruz MC, Ziyadeh FN. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-β-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 2002; 296: 1356–65.
  • 23
    Hu B, Wu Z, Phan SH. Smad3 mediates transforming growth factor-β-induced α-smooth muscle actin expression. Am J Respir Cell Mol Biol 2003; 29: 397–404.
  • 24
    Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, et al. Functional characterization of transforming growth factor β signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem 2001; 276: 19945–53.
  • 25
    Yang YC, Piek E, Zavadil J, Liang D, Xie D, Heyer J, et al. Hierarchical model of gene regulation by transforming growth factor-β. Proc Natl Acad Sci U S A 2003; 100: 10269–74.
  • 26
    Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, Heldin CH, et al. Elucidation of Smad requirement in transforming growth factor-β type I receptor-induced responses. J Biol Chem 2003; 278: 3751–61.
  • 27
    Hayashida T, DeCaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad-signaling pathways enhances TGF-β dependent responses in human mesangial cells. FASEB J 2003; 17: 1576–8.
  • 28
    Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, et al. Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol Pharmacol 2002; 62: 58–64.
  • 29
    Von Gersdorff G, Susztak K, Rezvani F, Bitzer M, Liang D, Bottinger EP. Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor-β. J Biol Chem 2000; 275: 11320–6.
  • 30
    Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112: 1486–94.
  • 31
    Lakos G, Takagawa S, Chen SJ, Ferreira AM, Han G, Masuda K, et al. Targeted disruption of TGF-β/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004; 165: 203–17.
  • 32
    Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-β: involvement of Smad 3. J Invest Dermatol 1999; 112: 49–57.
  • 33
    Varga J. Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 2002; 46: 1703–13.
    Direct Link:
  • 34
    Varga J. Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts. Curr Rep Rheumatol 2004; 6: 164–70.
  • 35
    Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 2002; 99: 3908–13.
  • 36
    Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253–64.
View Full Article (HTML) Get PDF (957K)